new glp 1 agonist novo nordisk Novo's Wegovy becomes first GLP-1 drug approved for MASH Novo Nordisk expands patient access
Description
Kaku, K., Rasmussen, M
Clinical characteristics of and risk factors for chronic kidney disease among adults and children: an analysis of the CURE-CKD registry
Diabetologia 2004
At 30 min (for pERK1/2 staining) or 90 min (for c-Fos staining) after injection, mice were transcardially perfused with phosphate buffer including 4% paraformaldehyde and 0.2% picric acid under anesthesia
Theres no getting around it: GLP-1 medications arent cheap
ICP was recorded with p-Tel telemetric ICP catheter and MPR-1 reader (Raumedic)
